Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus BECLOMETHASONE DIPROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus BECLOMETHASONE DIPROPIONATE.
ARMONAIR RESPICLICK vs BECLOMETHASONE DIPROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through binding to glucocorticoid receptors, leading to inhibition of phospholipase A2, reduced prostaglandin and leukotriene synthesis, and suppression of inflammatory cytokines.
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
Inhalation: 40-320 mcg twice daily (DPI or pMDI); maximum 640 mcg/day. Intranasal: 1-2 sprays (42-84 mcg) per nostril twice daily. Topical: Apply 0.025% cream/ointment twice daily.
None Documented
None Documented
Clinical Note
moderateBeclomethasone dipropionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gatifloxacin."
Clinical Note
moderateBeclomethasone dipropionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rosoxacin."
Clinical Note
moderateBeclomethasone dipropionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
Terminal elimination half-life is 2.8-3.1 hours after inhalation, with a slower phase attributed to slow dissolution from lung tissue; clinical context: supports twice-daily dosing.
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Primarily fecal (via bile) as metabolites, ~60-70%; renal excretion accounts for <10% of unchanged drug.
Category C
Category A/B
Inhaled Corticosteroid
Inhaled Corticosteroid
Beclomethasone dipropionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trovafloxacin."